does omega-3 or fish oil work for depression?

a little, on average, with very low certainty. the cochrane review of 35 randomised trials (1,924 adults with major depression) found a small-to-modest reduction in symptoms, about 2.5 points on the 17-item hamilton scale, below the 3-point change usually considered clinically meaningful, and no difference in remission or response. the reviewers judged the evidence very low certainty and likely biased in omega-3’s favour. a separate meta-analysis found the benefit concentrated in epa-heavy formulations at 1 g of epa a day or less, a pattern its own critics call exploratory.

does fish oil prevent depression?

the largest trial says no. 18,353 us adults aged 50 and over took 1 g a day of marine omega-3 or placebo for a median 5.3 years; depression or clinically relevant depressive symptoms occurred at 13.9 per 1,000 person-years on omega-3 against 12.3 on placebo, a small but statistically significant increase, with no difference in mood scores. the authors concluded the findings do not support omega-3 supplements for preventing depression. the result does not show that fish oil causes depression either.

was the omega-3 depression meta-analysis retracted?

no. the 2019 meta-analysis in translational psychiatry (liao and colleagues) carries a published erratum (2021) and a published critique (2022); neither is a retraction, and the harvest that built this page checked its pubmed record for retraction flags on 2026-08-18 and found none. the cochrane review of omega-3 for depression (appleton and colleagues, 2021) has not been retracted either. both belong beside their criticisms, not in place of them.

how much epa did the depression trials use, and what is in a fish-oil capsule?

the trials and the expert guideline are dosed in grams of epa: the 2019 meta-analysis found the benefit in formulations that were pure epa or at least 60% epa at doses of 1 g a day or less of epa, and the isnpr panel recommends 1 to 2 g of net epa daily. a capsule marked "fish oil 1000 mg" typically contains only a few hundred milligrams of epa, so the dose on the front of the bottle is usually not the trial dose. the fda does not check that a supplement contains what its label says.

is omega-3 fda approved, and is it safe?

not for depression or any psychiatric condition. prescription omega-3 drugs (icosapent ethyl, omega-3-acid ethyl esters) are approved for raised triglycerides and cardiovascular risk only. at supplement doses the usual effects are fishy aftertaste, nausea and loose stools; over 5.3 years at 1 g a day, bleeding and bruising were no more common than on placebo. the prescription 4 g a day epa label warns of atrial fibrillation and of bleeding, especially with aspirin, clopidogrel or warfarin. people with fish or shellfish allergy can react.

Supplement evidence

Omega-3

The depression meta-analyses, the EPA/DHA split, and the heterogeneity problem.

page first published 2026-09-08 · last updated 2026-10-05

Not an FDA-approved treatmentSold as a dietary supplement4 studies on this page

What Its Legal Status Actually Means

Read this before anything below it. Legal to sell is not the same fact as reviewed, verified, or approved.

Fish-oil, EPA and DHA products sold for mood are dietary supplements under DSHEA: no FDA review of safety or effectiveness happens before they go on sale, and none is approved to treat depression or any other psychiatric condition. Prescription omega-3 drugs do exist, but for lipids, not mood. Icosapent ethyl (Vascepa) is FDA-approved as an adjunct to maximally tolerated statin therapy to reduce cardiovascular events in adults with triglycerides at or above 150 mg/dL plus established cardiovascular disease or diabetes, and as an adjunct to diet for severe (at or above 500 mg/dL) hypertriglyceridemia; omega-3-acid ethyl esters (Lovaza and generics) are approved only as an adjunct to diet for severe hypertriglyceridemia. Neither label carries a psychiatric indication. Dose matters and labels obscure it: the depression literature is dosed in grams of EPA, while a capsule marked "fish oil 1000 mg" typically contains only a few hundred milligrams of EPA, so the number on the front of the bottle is usually not the number the trials used.

Quoted whole from the 2026-08-18 study harvest. Not summarized, not shortened.

does omega-3 (fish oil) work for depression? what the trials say

there is no fda label for omega-3 supplements, because they are sold as dietary supplements and have never been reviewed for effectiveness in depression. the prescription omega-3 drugs named below are approved for blood lipids, not mood. the regulatory facts come from the legal-status paragraph above, written from the regulator’s documents in the 2026-08-18 study harvest; every trial figure is from a study record on this page. every source is linked at the end of this section. last checked 2026-10-05.

fish oil is the supplement most often taken for mood, and it has more trial evidence behind it than almost any other: dozens of randomised trials, a cochrane review, and the largest prevention trial ever run. this section says what its legal status means, what the trials measured and for how long, what they found in both directions, why the dose on the bottle is usually not the dose the trials used, and what the "retracted" searches that bring people here are about. every number is from a study record on this page, and each source is linked at the end.

this is information to take to a prescriber or pharmacist. nothing here tells anyone to take omega-3 or to stop, and nothing here is a reason to put off treatment that works.

what its legal status means, and does not mean

fish-oil, epa and dha products sold for mood are dietary supplements under the 1994 dietary supplement health and education act: no fda review of safety or effectiveness happens before they go on sale, and none is approved to treat depression or any other psychiatric condition [status]. prescription omega-3 drugs do exist, but for lipids, not mood: icosapent ethyl (vascepa) is approved to reduce cardiovascular events in people with raised triglycerides on a statin and for severe hypertriglyceridemia, and omega-3-acid ethyl esters (lovaza and generics) only for severe hypertriglyceridemia. neither label carries a psychiatric indication [status].

dose matters and labels obscure it. the depression trials are dosed in grams of epa, one of the two main omega-3 fatty acids, while a capsule marked "fish oil 1000 mg" typically contains only a few hundred milligrams of epa, so the number on the front of the bottle is usually not the number the trials used [status].

what the trials measured, and for how long

the treatment evidence is dozens of short randomised trials in people with major depression, pooled twice. the cochrane review covers 35 trials, 34 of them against placebo, with 1,924 adults [cochrane-2021]; a 2019 meta-analysis covers 26 double-blind placebo-controlled trials with 2,160 participants [liao-2019]. both measure change on depression rating scales, mostly the 17-item hamilton scale, where a 3-point change is the smallest difference usually considered clinically meaningful [cochrane-2021].

the prevention evidence is one very large, very long trial: 18,353 us adults aged 50 and over randomised to 1 g a day of marine omega-3 (465 mg epa plus 375 mg dha) or placebo and followed for a median 5.3 years, with new depression or clinically relevant depressive symptoms as the outcome [vital-dep-2021]. it tests whether fish oil keeps depression away in people who did not have it, which is a different question from whether it treats depression someone already has.

what the research says, in both directions

in favour. across the 35 cochrane trials, omega-3 produced a small-to-modest reduction in depressive symptoms: a standardised mean difference of −0.40 (95% confidence interval −0.64 to −0.16), which the authors translate to roughly 2.5 points on the 17-item hamilton scale [cochrane-2021]. the 2019 meta-analysis found an overall effect of −0.28 and that the benefit was concentrated in formulations that were pure epa or at least 60% epa at doses of 1 g a day or less of epa (−0.50 and −1.03 in those subgroups), while dha-dominant formulations showed no benefit [liao-2019]. an expert panel of the international society for nutritional psychiatry research recommends, for major depression, pure epa or an epa-to-dha ratio above 2:1 at 1 to 2 g of net epa daily, alongside proper diagnosis, measurement-based assessment, and monitoring for gastrointestinal and skin side effects [isnpr-2019]. the supplement is also well tolerated: over 5.3 years at 1 g a day, gastrointestinal bleeding occurred in 2.6% on omega-3 and 2.7% on placebo, and easy bruising in 24.8% against 25.1% [risks].

against, or smaller than the badge suggests. the cochrane effect of about 2.5 points sits below the 3-point change usually considered meaningful; there was no evidence of a difference in remission (odds ratio 1.13) or response (odds ratio 1.20); the reviewers graded the evidence very low certainty; and funnel plots, sensitivity analyses and comparison with the large well-conducted trials all suggested the estimate is biased in omega-3’s favour [cochrane-2021]. the 2019 subgroup pattern about epa dose is a hypothesis drawn from heterogeneous small trials, not a tested rule, and that paper carries a published erratum (2021) and a published critique (2022), neither of them a retraction [liao-2019]. the prevention trial was flat: depression or clinically relevant depressive symptoms occurred at 13.9 per 1,000 person-years on omega-3 against 12.3 on placebo (hazard ratio 1.13, p = .03), a small but statistically significant increase, with no difference in mood scores, and the authors concluded the findings do not support omega-3 supplements to prevent depression [vital-dep-2021]. that higher rate was a borderline result on one of two co-primary outcomes while the other showed nothing, so it does not show that omega-3 causes depression either [vital-dep-2021]. and the expert panel recommending 1 to 2 g of epa is a society organised around nutritional psychiatry, writing a guideline for the intervention it exists to promote, with panel members whose own trials form part of the evidence; two letters challenging the guideline appeared in the same journal [isnpr-2019].

read together: a small average effect on symptom scores, no effect on remission or response, no prevention, and a dose question the bottles do not answer. the cochrane authors’ verdict, very low certainty, is the one to hold.

the risks the harvest recorded

omega-3 supplements are generally well tolerated; the usual complaints are fishy aftertaste or burps, nausea, loose stools and heartburn [risks]. bleeding risk at ordinary supplement doses is largely theoretical, as the 5.3-year trial numbers above show. the real signal appears at high prescription doses: the fda label for icosapent ethyl at 4 g a day of epa carries warnings for atrial fibrillation or flutter requiring hospitalisation and for bleeding, with bleeding risk greater in people also taking aspirin, clopidogrel or warfarin [risks]. people with fish or shellfish allergy can react to fish-derived products [risks].

the most important practical risk is not toxicity but substitution: the largest prevention trial found omega-3 did not prevent depression, and the cochrane treatment estimate sits below the threshold for a meaningful change, so relying on it instead of a treatment that works is the more likely harm [risks].

questions for a prescriber or pharmacist about omega-3

each one comes from a warning or a study above. they are questions, not instructions; the answers depend on a history nobody here has.

the best synthesis puts omega-3’s effect on depression at about 2.5 points on a scale where 3 is the smallest change that matters. is adding it worth it for me, or is that effort better spent on something with a bigger effect?
if we try it, does the product i would buy actually deliver about a gram of epa a day, with epa making up most of the total? the front of the bottle usually gives the fish-oil weight, not the epa.
am i taking it to prevent depression? the largest trial found it did not, and if anything nudged the rate slightly up.
one expert group recommends 1 to 2 g of epa a day and the cochrane review says the evidence is very low certainty. which should guide what i do?
i take aspirin, clopidogrel or warfarin. the bleeding warning is on the prescription 4 g label, not the supplement; does it apply to the dose i am considering?
how would we tell, after eight weeks, whether it did anything?

questions people ask

does omega-3 or fish oil work for depression?: a little, on average, with very low certainty. the cochrane review of 35 randomised trials (1,924 adults with major depression) found a small-to-modest reduction in symptoms, about 2.5 points on the 17-item hamilton scale, below the 3-point change usually considered clinically meaningful, and no difference in remission or response. the reviewers judged the evidence very low certainty and likely biased in omega-3’s favour. a separate meta-analysis found the benefit concentrated in epa-heavy formulations at 1 g of epa a day or less, a pattern its own critics call exploratory.
does fish oil prevent depression?: the largest trial says no. 18,353 us adults aged 50 and over took 1 g a day of marine omega-3 or placebo for a median 5.3 years; depression or clinically relevant depressive symptoms occurred at 13.9 per 1,000 person-years on omega-3 against 12.3 on placebo, a small but statistically significant increase, with no difference in mood scores. the authors concluded the findings do not support omega-3 supplements for preventing depression. the result does not show that fish oil causes depression either.
was the omega-3 depression meta-analysis retracted?: no. the 2019 meta-analysis in translational psychiatry (liao and colleagues) carries a published erratum (2021) and a published critique (2022); neither is a retraction, and the harvest that built this page checked its pubmed record for retraction flags on 2026-08-18 and found none. the cochrane review of omega-3 for depression (appleton and colleagues, 2021) has not been retracted either. both belong beside their criticisms, not in place of them.
how much epa did the depression trials use, and what is in a fish-oil capsule?: the trials and the expert guideline are dosed in grams of epa: the 2019 meta-analysis found the benefit in formulations that were pure epa or at least 60% epa at doses of 1 g a day or less of epa, and the isnpr panel recommends 1 to 2 g of net epa daily. a capsule marked "fish oil 1000 mg" typically contains only a few hundred milligrams of epa, so the dose on the front of the bottle is usually not the trial dose. the fda does not check that a supplement contains what its label says.
is omega-3 fda approved, and is it safe?: not for depression or any psychiatric condition. prescription omega-3 drugs (icosapent ethyl, omega-3-acid ethyl esters) are approved for raised triglycerides and cardiovascular risk only. at supplement doses the usual effects are fishy aftertaste, nausea and loose stools; over 5.3 years at 1 g a day, bleeding and bruising were no more common than on placebo. the prescription 4 g a day epa label warns of atrial fibrillation and of bleeding, especially with aspirin, clopidogrel or warfarin. people with fish or shellfish allergy can react.

sources for this section

the library rows link to our one-page summary of each study, with the original paper, its funding and our evidence grade on that page.

What the Research Shows

4 records from the 2026-08-18 harvest, each checked against PubMed and Europe PMC on that date. How a study was designed, how many people were in it, and who paid for it are printed above what it found, because those three facts decide how much the finding is worth.

Study 1 · 2021
- Systematic review of randomized trials
- 1,924 participants
- Top-tier journal
- Independently funded
- Preregistered
- Declared conflicts of interest
gold standard97/100
Top of the evidence hierarchy, independently funded.
Across 35 randomised trials (34 versus placebo, 1,924 adults with major depressive disorder), omega-3 supplementation produced a small-to-modest reduction in depressive symptoms — standardised mean difference -0.40 (95% CI -0.64 to -0.16), which the authors translate to roughly 2.5 points on the 17-item Hamilton scale, below the 3.0-point change usually considered clinically meaningful. There was no evidence of a difference in remission (OR 1.13, 95% CI 0.74 to 1.72) or response (OR 1.20, 95% CI 0.80 to 1.79). The reviewers graded the evidence very low certainty and reported that funnel-plot inspection, sensitivity analyses, and comparison with large well-conducted trials all suggest the estimate is biased in omega-3's favour.
Appleton KM, Voyias PD, Sallis HM, Dawson S, Ness AR, Churchill R, Perry R. (2021). Omega-3 fatty acids for depression in adults. Cochrane Database of Systematic Reviews. PMID 34817851.
How this record was checked
PubMed record 34817851 fetched via NCBI efetch 2026-08-18; title, all seven authors, journal, year, DOI, N=1924 participants across 35 studies, and the SMD -0.40 (95% CI -0.64 to -0.16) confirmed from the abstract. PMC full text PMC8612309 read 2026-08-18: "Sources of support" lists Bournemouth University and University of Bristol (internal) and the National Institute for Health Research (external), hence funding INDEPENDENT; the same page records "Protocol first published: Issue 1, 2004", hence preregistered true, and a per-author declarations-of-interest section, hence conflicts true.
Study 2 · 2021
- Randomized trial
- 18,353 participants
- Top-tier journal
- Mixed funding
- Preregistered
- Declared conflicts of interest
gold standard85/100
Top of the evidence hierarchy, independently funded.
Read this first: The higher depression rate was a borderline result on one of two coprimary outcomes while the other (mood scores) showed nothing at all; the authors did not claim omega-3 causes depression, and this was a prevention trial in people without clinically relevant depressive symptoms at baseline, so it does not test omega-3 as a treatment for existing depression. Study capsules and matching placebo were donated by Pronova BioPharma, an industry in-kind contribution, though the trial itself was NIH-funded, the funders had no role, and the result was unfavourable to the product.
In 18,353 US adults aged 50 and older randomised to 1 g/day of marine omega-3 (465 mg EPA plus 375 mg DHA) or matching placebo for a median 5.3 years, omega-3 did not prevent depression: depression or clinically relevant depressive symptoms occurred at 13.9 per 1,000 person-years on omega-3 versus 12.3 on placebo (HR 1.13, 95% CI 1.01 to 1.26, P=.03) — a small but statistically significant increase in risk. Mood scores did not differ (mean PHQ-8 change difference 0.03 points, 95% CI -0.01 to 0.07). The authors concluded the findings do not support using omega-3 supplements to prevent depression in adults.
Okereke OI, Vyas CM, Mischoulon D, Chang G, Cook NR, et al. (2021). Effect of Long-term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. JAMA. PMID 34932079.
How this record was checked
PubMed record 34932079 fetched via NCBI efetch 2026-08-18; title, authors, journal (JAMA 2021;326(23):2385-2394), DOI, N=18,353 randomised, the hazard ratio, and the PHQ-8 difference confirmed from the abstract, along with trial registrations NCT01696435 and NCT01169259 (hence preregistered true) and a conflict-of-interest disclosure statement (hence conflicts true). Europe PMC core record fetched 2026-08-18 lists NIH grants including R01 MH091448 (NIMH). PMC full text PMC8693224 read 2026-08-18: "Funding/Support" confirms NIH grant support and states "The study agents, matching placebo, and packaging were donated by Pharmavite LLC (vitamin D) and Pronova BioPharma (fish oil)" — public funding with industry in-kind product, hence MIXED.
Study 3 · 2019
- Meta-analysis of randomized trials
- 2,160 participants
- Reputable journal
- Independently funded
- Declared conflicts of interest
gold standard89/100
Top of the evidence hierarchy, independently funded.
Read this first: The paper carries a published erratum (Transl Psychiatry 2021;11(1):465) and a published critique (Transl Psychiatry 2022;12(1):298); neither is a retraction, but both belong alongside it. Dose and formulation subgroups drawn out of a meta-analysis of heterogeneous small trials are exploratory — the Cochrane review reached a similar overall effect size and judged it very low certainty and likely biased upward.
Pooling 26 double-blind placebo-controlled trials (2,160 participants), omega-3 had an overall effect on depressive symptoms of SMD -0.28 (P=0.004) — small. The benefit was concentrated in formulations that were pure EPA or at least 60% EPA at doses of 1 g/day or less of EPA (SMD -0.50 and -1.03 respectively), while DHA-pure and DHA-predominant formulations showed no benefit. The pooled effect is smaller than the change most clinicians would notice, and the subgroup pattern is a hypothesis about dosing, not a tested rule.
Liao Y, Xie B, Zhang H, He Q, Guo L, Subramanieapillai M, Fan B, Lu C, McIntyre RS. (2019). Efficacy of omega-3 PUFAs in depression: A meta-analysis. Translational Psychiatry. PMID 31383846.
How this record was checked
PubMed record 31383846 fetched via NCBI efetch 2026-08-18; title, all nine authors, journal, year, DOI, 26 studies, N=2,160 participants, and SMD -0.28 (P=0.004) confirmed from the abstract, which also carries the statement "The authors declare that they have no conflict of interest" (hence conflicts true) and the "Erratum in" and "Comment in" flags noted above. Europe PMC core record fetched 2026-08-18 lists a single funder, the National Natural Science Foundation of China, hence funding INDEPENDENT.
Study 4 · 2019
- Clinical guideline
- Reputable journal
- Funding not established
moderate60/100
Reasonable evidence with real limitations.
Read this first: ISNPR is a society organised around nutritional psychiatry, so it is the proponent of the intervention it is writing guidelines for, and the panel includes investigators whose own omega-3 trials form part of the evidence base being summarised. Two letters challenging the guideline appeared in the same journal (Psychother Psychosom 2020;89(1):48, PMID 31655818, and the authors' reply at 89(1):49, PMID 31743919). No funding statement was located, so funding is recorded UNKNOWN.
An expert panel convened by the International Society for Nutritional Psychiatry Research used a literature review and Delphi consensus process to recommend, for major depressive disorder, either pure EPA or an EPA/DHA formula with a ratio above 2:1, at 1-2 g of net EPA daily, alongside proper diagnosis, measurement-based assessment, and monitoring for gastrointestinal and skin side effects. This is consensus expert opinion rather than new trial evidence, and it sits uneasily beside the Cochrane review's verdict that the certainty of the evidence is low to very low.
Guu TW, Mischoulon D, Sarris J, Hibbeln J, McNamara RK, et al. (2019). International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder. Psychotherapy and Psychosomatics. PMID 31480057.
How this record was checked
PubMed record 31480057 fetched via NCBI efetch 2026-08-18; title, authors, journal (Psychother Psychosom 2019;88(5):263-273), year, and DOI confirmed against the record, along with the 1-2 g net EPA daily and EPA/DHA >2 recommendations quoted from the abstract. The two "Comment in" letters (PMIDs 31655818 and 31743919) were fetched in the same batch and their titles confirmed. Europe PMC core record checked 2026-08-18: no grant list and no funding statement available, so funding recorded UNKNOWN and conflicts false (no disclosure statement read).

The Risks

Nobody checks this purchase the way a prescription is checked. No prescriber reviews it against the rest of what you take, no pharmacist screens the interaction, and no regulator confirms the dose in the capsule before it is sold. That is why this section sits here at full length rather than as a footnote.

What the paragraph below covers:

Heart and blood pressure
Drug interactions
Stomach and gut

Omega-3 supplements are generally well tolerated; the usual complaints are fishy aftertaste or burps, nausea, loose stools, and heartburn. Bleeding risk at ordinary supplement doses is largely theoretical — over a median 5.3 years at 1 g/day in 18,353 adults, gastrointestinal bleeding occurred in 2.6% on omega-3 versus 2.7% on placebo, and easy bruising in 24.8% versus 25.1%. The real signal appears at high prescription doses: the FDA label for icosapent ethyl (4 g/day EPA) carries warnings for atrial fibrillation or flutter requiring hospitalisation and for bleeding, with bleeding risk greater in people also taking aspirin, clopidogrel, or warfarin. People with fish or shellfish allergy can react to fish-derived products. The most important practical risk is not toxicity but substitution: the largest prevention trial found omega-3 did not prevent depression, and the Cochrane estimate of its treatment effect sits below the threshold for a clinically meaningful change, so relying on it instead of a treatment that works is the more likely harm.

What Is Not Known

The boundaries of the section above, in the harvest’s own words. What it excluded, why, and where it looked and found nothing. An absence of evidence is not evidence of absence, and it is not evidence of benefit either.

What Was Left Out, and Why

Quoted from the harvest, where these notes sat above the study list rather than after it. Where a note says “below” it means the studies in the section above.

Individual small positive EPA trials (Peet 2002, Nemets 2002, Su 2003, etc.) excluded in favour of the Cochrane review and the dose meta-analysis below, which subsume them.
The two published letters criticising the ISNPR guideline (PMIDs 31655818 and 31743919, both Psychother Psychosom 2020;89(1)) were fetched and are cited inside that study's contestedNote rather than listed as separate records.
VITAL-DEP's vitamin-D arm and the omega-3 cardiovascular literature are out of scope; only the depression endpoint paper is included.

The Retraction Check

PubMed efetch records for all four PMIDs inspected 2026-08-18 for "Retraction in" flags; none present. Liao 2019 (31383846) carries an "Erratum in" (Transl Psychiatry 2021;11(1):465) and a published "Comment in" critique (Transl Psychiatry 2022;12(1):298) — neither is a retraction; both noted in contestedNote.

Questions for a Prescriber or Pharmacist

This page does not tell anyone to take Omega-3 or to avoid it. It is not able to: it does not know what else you take, what you have tried, or what you are treating. These are the questions each study above raises, written to be asked out loud.

The best synthesis puts omega-3's effect on depression at about 2.5 points on a scale where 3 points is the smallest change that matters — is adding it worth it for me, or is that effort better spent on something with a bigger effect?
The largest trial ever run found fish oil did not prevent depression and if anything nudged the risk slightly up — am I taking it for prevention, and if so is there any reason to keep going?
If we're going to try omega-3 at all, does the product I'd be buying actually deliver about a gram of EPA a day, with EPA making up most of the total?
One expert group recommends 1-2 grams of EPA a day for depression while the Cochrane review says the evidence is very low certainty — which of those should guide what I actually do?

And the one to ask at the counter, whatever the answers above turn out to be: given everything I am already taking, what would you want to know about Omega-3 before I put it in the same body?

Open Omega-3 in veisund

The app has the resources behind this page and people working through the same questions.What you post there goes to people, not to a model. If someone answers, it is a person who has been there. The one automated message is a crisis-resource reply.

Where This Page Comes From

Transcribed from the study-harvest-2026-08-18 record for omega-3, built into this page by scripts/supplement-ingest.mjs on 2026-09-07. Nothing here is fetched at page load, and nothing here was written by a model without a citation behind it.

Source file	study-harvest/2026-08-18/omega-3.yaml
Source repo	REPTechnologies/avalo-backend
SHA-256	c44385adfe003cb4e8a54afe446cd0925cb53893e0df90624d555bbc34217e53
Also searched as	fish oil, EPA, DHA, n-3 PUFA, omega-3 fatty acids, krill oil, algal oil

The Other Substances

Do any supplements actually work? asks the question across all of them. The full library has the medication records, the funding investigations, and the glossary.